oxybutynin + mirabegron

This drug entry refers to the standardized pharmacotherapy regimen of oxybutynin and mirabegron utilized in a clinical trial led by Emilio José Dávila Álvarez for the treatment of urgency urinary incontinence (UUI). Oxybutynin is a muscarinic antagonist that works by blocking M1, M2, and M3 receptors in the bladder, thereby inhibiting involuntary detrusor contractions. Mirabegron is a selective beta-3 adrenergic receptor agonist that induces detrusor relaxation and increases bladder capacity during the urine storage phase. In the context of the trial, oxybutynin is administered as a first-line treatment, with mirabegron serving as an alternative or adjunct for patients who experience intolerance or inadequate response to anticholinergic therapy. The study evaluates this pharmacological approach alongside behavioral interventions and pelvic floor muscle training.

Other names

oxybutynin and mirabegron combination